Possible scenario
Adoption Accelerates
42% Chance
The obesity decline becomes credible evidence that GLP-1s are producing population-level health effects. Employers, Medicare Advantage plans, and commercial insurers broaden access because weight loss, diabetes prevention, and cardiovascular benefits start to justify the drug budget.
Secondary impacts
- Healthcare +1.4%
- Consumer Non-Cyclicals -0.9%
- Consumer Services -0.3%
- Consumer Cyclicals +0.3%
Tickers
- LLY+3.4%
- MDLZ-1.0%
- -0.9%
Portfolio impact
S&P 500+0.1%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.